Acute renal failure in the critically ill

Current Opinion in Anaesthesiology

Volumn 18, Issue 2, 2005, Pages 117-122

  Venkataraman, Ramesh ^a   Kellum, John A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute renal failure; Bone morphogenic protein 7; Dialysis; Diuretics; Erythropoietin; Recovery; Treatment

Indexed keywords

ACETYLCYSTEINE; ANARITIDE; ATRIAL NATRIURETIC FACTOR; CONTRAST MEDIUM; CREATININE; DOPAMINE; ERYTHROPOIETIN; FENOLDOPAM; IODIXANOL; IOHEXOL; LOOP DIURETIC AGENT; OSTEOGENIC PROTEIN 1; PLACEBO; THEOPHYLLINE;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; CREATININE CLEARANCE; CRITICAL ILLNESS; DIALYSIS; FLUID THERAPY; HEMODIALYSIS; HEMOFILTRATION; HOSPITALIZATION; HUMAN; HYPOTENSION; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 17144417219     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000162828.51399.1b     Document Type: Review

References (57)

1. Nissenson AR. Acute renal failure: definition and pathogenesis. Kidney Int Suppl 1998; 66:7-10.
2. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74:243-248.
3. Bellomo R, Ronco C. The changing pattern of severe acute renal failure. Nephrology 1991; 2:602-610.
4. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212. This paper describes the RIFLE classification and its rationale as well as consensus recommendations for outcome measures, animal models, fluid therapy and information technology in ARF.
5. Chertow GM, Levy EM, Hammermeister KE, et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104:343-348.
6. Hoste EA, Lameire NH, Vanholder RC, et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003; 14:1022-1030.
7. Kellum JA, Angus DC. Patients are dying of acute renal failure. Crit Care Med 2002; 30:2156-2157.
8. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30:2051-2058.
9. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416-1420.
10. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93:C29-C34.
11. Better OS, Rubinstein I. Management of shock and acute renal failure in casualties suffering from the crush syndrome. Ren Fail 1997; 19:647-653.
12. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-336.
13. Metten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328-2334. This paper was the first to compare 0.9% saline to sodium bicarbonate for the prevention of contrast nephropathy. While underpowered, the intervention used in this study is simple, and inexpensive.
14. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188:171-178.
15. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499. Although this study did not include a cost-effectiveness analysis, and the isoosmolar agent used is considerably more expensive, this agent would appear to be indicated for most high-risk patients.
16. Kellum JA. The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Critical Care 1997; 1:53-59.
17. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547-2553.
18. Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669-1677. This paper is the largest, multi-national, multi-center observational study that evaluated the role of diuretic use on clinical outcome in patients with ARF. The results, while not showing harm from diuretics, fail to demonstrate any benefit.
19. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29:1526-1531.
20. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med 2002; 28:877-883.
21. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-2143.
22. Halpenny M, Lakshmi S, O'Donnell A, et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001; 56:953-960.
23. Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 2002; 19:32-39.
24. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143:894-903.
25. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290:2284-2291. This study is the largest RCT evaluating the role of fenoldopam in prevention of ARF.
26. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27:1832-1837.
27. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336:828-834.
28. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36:767-774.
29. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32:1310-1315.
30. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994; 45:1425-1431.
31. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media- induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999; 14:1146-1149.
32. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998; 11:151-156.
33. Kramer BK, Preuner J, Ebenburger A, et al. Lack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant 2002; 17:910-915.
34. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004; 19:2747-2753.
35. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40:298-303.
36. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89:356-358.
37. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62:2202-2207.
38. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180-184.
39. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43:1-9.
40. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362:598-603. A methodologically rigorous metaanalysis clearly demonstrating an effect of NAC on serum creatinine. The study does not settle whether the drug prevents ARF, however.
41. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003; 92:1454-1458.
42. Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15:407-410. This study raises an important point that NAC can decrease serum creatinine concentrations without affecting GFR.
43. Subramanian S, Venkataraman R, Kellum JA. Influence of dialysis membranes on outcomes in acute renal failure: a meta-analysis. Kidney Int 2002; 62:1819-1823.
44. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26-30.
45. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305-310.
46. Mehta RL, McDonald B, Gabbai FB, et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001; 60:1154-1163.
47. Kellum JA, Angus DC, Johnson JP, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002; 28:29-37.
48. Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002; 40:875-885.
49. Kellum JA, Mehta RL, Angus DC, et al. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002; 62:1855-1863.
50. Gettings LG, Reynolds HN, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. Intensive Care Med 1999; 25:805-813.
51. Bouman CSC, Oudemans-van Straaten HM, Tijssen JGP. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective randomized trial. Crit Care Med 2002; 30:2205-2211.
52. Venkataraman R, Kellum JA. Novel approaches to the treatment of acute renal failure. Expert Opin Investig Drugs 2000; 9:2579-2592.
53. Allen BT, Anderson CB, Rubin BG, et al. Preservation of renal function in juxtarenal and suprarenal abdominal aortic aneurysm repair. J Vasc Surg 1993; 17:948-958.
54. Franklin SC, Moulton M, Sicard GA, et al. Insulin-like growth factor I preserves renal function postoperatively. Am J Physiol 1997; 272:257-259.
55. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999; 55:2423-2432.
56. Liangos O, Pereira BJ, Jaber BL. Anemia in acute renal failure: role for erythropoiesis-stimulating proteins? Artif Organs 2003; 27:786-791.
57. Westenfelder C. Unexpected renal actions of erythropoietin. Exp Nephrol 2002; 10:294-298.